Ventas (VTR)

• Market cap: $28.9B
• 1 day: -1.15%
• 5 days: 2.01%
• 1 month: 9.60%
• 3 months: 2.77%
• 6 months: 12.40%
• Year to date: 14.01%
• 1 year: 49.91%
• 5 years: 4.91%
• 10 years: -14.82%
• Sector: Financials
• Industry: Real Estate Investment Trusts

About: Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.

Employees: 498

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

43% more first-time investments, than exits

New positions opened: 99 | Existing positions closed: 69

28% more repeat investments, than reductions

Existing positions increased: 290 | Existing positions reduced: 227

1% more funds holding

Funds holding: 710 [Q3] → 720 (+10) [Q4]

5% more call options, than puts

Call options by funds: $47.5M | Put options by funds: $45.5M

4.31% less ownership

Funds ownership: 101.51% [Q3] → 97.2% (-4.31%) [Q4]

7% less capital invested

Capital invested by funds: $27B [Q3] → $25B (-$1.92B) [Q4]

27% less funds holding in top 10

Funds holding in top 10: 15 [Q3] → 11 (-4) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $65 2% downside
• Avg. target: $70 6% upside
• High target: $78 18% upside

4 analyst ratings

• positive: 3 75%
• neutral: 1 25%
• negative: 0 0%

Wedbush Richard Anderson 62% 1-year accuracy 21 / 34 met price target	18% upside $78	Outperform Maintained	14 Feb 2025
Scotiabank Nicholas Yulico 51% 1-year accuracy 19 / 37 met price target	4% upside $69	Sector Perform Maintained	27 Jan 2025
Baird David Rodgers 61% 1-year accuracy 17 / 28 met price target	2% downside $65	Outperform Upgraded	17 Jan 2025
Mizuho Vikram Malhorta 89% 1-year accuracy 16 / 18 met price target	3% upside $68	Outperform Maintained	5 Dec 2024